

Vosevi® (SOF/VEL/VOX) Storage and Stability

This document is in response to your request for extended storage and stability information of Vosevi® (sofosbuvir/velpatasvir/voxilaprevir [SOF/VEL/VOX]) 400/100/100 mg tablets and does not intend to offer an opinion regarding the clinical relevance of these data or the advisability of storing or administering any drug in a manner inconsistent with its approved labeling. Vosevi® (SOF/VEL/VOX) should be stored according to the product label.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vosevi/vosevi_pi.

Product Labeling¹

Each bottle contains 28 tablets, polyester coil, silica gel desiccant, and is closed with a child-resistant closure. Store below 30°C (86°F). Dispense only in original container.

Alternative Storage and Stability Information²

The table below summarizes available data from in-house studies regarding the storage of SOF/VEL/VOX tablets in varying conditions. The "acceptable duration" refers to the stability of SOF/VEL/VOX tablets in the specified packaging and storage condition, but it does not endorse alternative packaging or use beyond the expiration date stated on the original packaging.

Table 1. Summary of Extended Stability Data for SOF/VEL/VOX Tablets²

Storage Condition	Package Type	Acceptable Duration
25°C (77°F)/60% relative humidity ^a	Petri dish	4 weeks
30°C (86°F)/75% relative humidity	Original bottle, broken seal	60 days
40°C (104°F)/75% relative humidity	Original bottle	6 months
60°C (140°F)	Original bottle	14 days
-20°C (-4°F)	Original bottle	14 days

^aTablets are stored outside of the commercial packaging configuration in an open petri dish in a stability chamber.

References

- 1. Enclosed. Gilead Sciences Inc, VOSEVI® (sofosbuvir/velpatasvir/voxilaprevir [SOF/VEL/VOX]) tablets, for oral use. US Prescribing Information. Foster City, CA.
- 2. Gilead Sciences Inc. Data on File.

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Vosevi US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vosevi/vosevi pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety 1-800-445-3235, option 3 or https://www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by 1-800-FDA-1088 or MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.

VOSEVI, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2025 Gilead Sciences. Inc.